The global dilated cardiomyopathy market size is projected to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising prevalence of heart diseases.
Dilated cardiomyopathy makes the muscular walls of the heart weak due as the expansion of the organ leads to inefficient pumping of the blood. This cardiac disorder not only affects heart but lungs and liver too. It is the medical condition that causes expansion of left vertical of the heart, which is referred to as the pumping chamber. Consequently, it expand to the right chamber with time. Dilated cardiomyopathy leads to frequent irregular heartbeats, blood clots, and valve problems, which may affect any individual irrespective of sex and age. The male to female ratio of this disorder is 3:1.
Infections in genetics, birth defects, cardiac muscles, excess drug or alcohol abuse, and exposure to toxic substances can cause this medical condition. In some cases, it can occur as a side effect of cancer treatment. The key symptoms of this medical condition includes swelling on lower extremities, shortness of breath, fatigue, sudden fainting, chest pain, dizziness, and blood clots.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing prevalence of cardiac disorder caused by expansion of heart muscles is expected to boost the dilated cardiomyopathy market.
- Rising lifestyle disorders and consumption of drug or alcohol are key factors fueling the market growth.
- Growing geriatric population is estimated to accelerate the growth of the market.
- Increasing health awareness can restrain the growth of the market.
- Government initiatives to control the chronicle diseases and policies in favor of the industry is estimated to foster the market growth.
Scope of the Report
The report on the dilated cardiomyopathy market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Dilated Cardiomyopathy Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Products (Diuretics, Beta-blockers, Digitalis, Warfarin, Angiotensin 2 Receptor Blocker, Diuretics, and Angiotensin-converting Enzyme Inhibitors), and Technology (Oral Drug and Implantable Devices)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Aastrom Biosciences, Inc.; Kasiak Research Pvt.Ltd.; t2cure GmbH; MyoKardia, Inc.; Capricor Therapeutics, Inc.; and Zensun Sci & Tech Co., Ltd.
|
Dilated Cardiomyopathy Market Segment Insights
Diuretics segment is expected to grow at a rapid pace
Based on products, the market is divided into diuretics, beta-blockers, digitalis, warfarin, angiotensin 2 receptor blocker, and angiotensin-converting enzyme inhibitors. The diuretics segment is estimated to account for a significant share of the market owing to presence of large product array in the market. However, the warfarin segment is anticipated to expand at a rapid pace during the forecast period due to rising adoption rate among hospitals.
Oral drug segment is projected to expand at a considerable CAGR
In terms of technology, the dilated cardiomyopathy market is bifurcated into oral drug and implantable devices. The oral drug segment to account for a key share of the market due to increasing awareness in patients and growing healthcare expenditure. Conversely, the implantable devices segment is anticipated to expand at a rapid pace during the forecast period owing to advancement in technology.
North America is anticipated to constitute a large market share
In terms of regions, the global market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America to account for a large market share due to increasing number of heart patients in the US. The market of Asia Pacific is anticipated to expand at a rapid pace during the forecast period owing to rapid development in healthcare infrastructure.
Segments
The global dilated cardiomyopathy market has been segmented on the basis of
Products
- Diuretics
- Beta-blockers
- Digitalis, Warfarin
- Angiotensin 2 Receptor Blocker
- Diuretics
- Angiotensin-converting Enzyme Inhibitors
Technology
- Oral Drug
- Implantable Devices
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Aastrom Biosciences, Inc.
- Kasiak Research Pvt.Ltd.
- t2cure GmbH
- MyoKardia, Inc.
- Capricor Therapeutics, Inc.
- Zensun Sci & Tech Co., Ltd
Competitive Landscape
Key players competing in the dilated cardiomyopathy market are Aastrom Biosciences, Inc.; Kasiak Research Pvt.Ltd.; t2cure GmbH; MyoKardia, Inc.; Capricor Therapeutics, Inc.; and Zensun Sci & Tech Co., Ltd.
The market players are continuously indulging in the activities such as mergers and acquisitions, research and developments, and increasing their investments for development of innovative products.
Request For Customization
Enquiry Before Buying
Speak With Analyst
